1stOncology™: Cancer Intelligence Service – Page 14734 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

10-Q – Quarterly report [Sections 13 or 15(d)]

Leap Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Leap Therapeutics, 2017, AUG 11, 2017, View Source [SID1234521978]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

10-Q – Quarterly report [Sections 13 or 15(d)]

Altimmune has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Altimmune, 2017, AUG 11, 2017, View Source [SID1234521254]).

10-Q – Quarterly report [Sections 13 or 15(d)]

Marina Biotech has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Marina Biotech, AUG 11, 2017, View Source [SID1234520237]).

Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology

On August 10, 2017 Takeda Pharmaceutical Company Limited (TSE: 4502) and Shattuck Labs, Inc. reported that they have entered into a research collaboration to explore and develop checkpoint fusion proteins that have the potential to become highly differentiated, next-generation immunotherapies (Press release, Takeda, AUG 10, 2017, View Source [SID1234598132]). Under the terms of the collaboration agreement, Takeda will hold options for exclusive global development and commercialization rights for up to four molecules resulting from the collaboration.

Shattuck Lab’s Agonist Redirected Checkpoint (ARC) platform combines two binding domains to create fusion proteins that potentially restore and enhance immune system function in a single construct. The ARC molecules block checkpoint molecules while simultaneously stimulating TNF superfamily co-stimulatory receptors on T-cells and innate cells, which are targets controlling the immune system and often dysregulated in cancers, thereby enabling combination immunotherapy with a single product.

"Shattuck Labs has pioneered the unique ARC platform, and we are excited about the opportunity this collaboration presents to develop groundbreaking, next-generation immunooncology treatments," said Christopher Arendt, Ph.D., Head, Oncology DDU & Immunology Unit, Takeda. "Research partnerships are a key aspect of our continued dedication to oncology innovation, and this collaboration will bring us closer to our goal of discovering, developing and delivering breakthrough oncology therapies."

The collaboration will include two pre-clinical and four discovery stage programs. Takeda will provide funding for pre-clinical and clinical development and will have the option to take an exclusive license to further develop and commercialize up to four ARC molecules resulting from the collaboration. Additional terms of the collaboration are not disclosed. "Takeda shares our passion and mission to develop and advance novel therapies in oncology, with the goal of achieving better clinical outcomes in patients," said Josiah Hornblower, Chairman and CEO of Shattuck Labs. "We are very excited to work with Takeda, a proven leader in oncology, to continue to validate the ARC technology."

Takeda signed the collaboration agreement through its wholly-owned subsidiary, Millennium
Pharmaceuticals, Inc.

Biotecnol and CRUK to Trial New Immuno-Oncology Treatment for Advanced Solid Tumours

On August 10, 2017 Biotecnol LImited and Cancer Research UK (CRUK), reported that an experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumours, including lung cancers, under a collaboration agreement between Cancer Research UK and Biotecnol Limited (Press release, Biotecnol, AUG 10, 2017, View Source [SID1234570282]).

Cancer Research UK will support the early clinical development of the company’s promising first-in-class drug called Tb535H.

The drug is the first to emerge from Biotecnol’s novel antibody development platform, Trisoma. It is directed against the 5T4/WAIF1 tumour antigen, a protein found on many different solid tumours and is thought to contribute to the spread of cancer cells.

Tb535H recruits the patient’s T-cells –killer cells of the immune-system – and directs them to attack tumours. This highly targeted approach uses the patient’s own immune system to fight cancer.

The WAIF1 antigen was discovered by scientists at the Cancer Research UK Manchester Institute. It could be a valuable target in many different cancer types, but the initial focus in this trial will be to treat cancers with high unmet-need.This includes thoracic cancers such as mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), for which survival remains very low, and renal cell carcinoma.

Under the agreement, Biotecnol and Cancer Research UK’s Centre for Drug Development will collaborate to take forward Tb535H through a Biotecnol-sponsored first-in-man Phase I clinical trial, using Cancer Research UK’s drug development expertise in return for shareholdings in Biotecnol.

Pedro de Noronha Pissarra, chief executive officer of Biotecnol said: "We’re very proud to work with Cancer Research UK on the development of advanced clinical trial approaches in this competitive and highly promising field of immuno-oncology.

"The collaboration is important for Biotecnol’s strategy of working with top cancer institutions in the immune-oncology field which will accelerate the development of cutting-edge therapeutic approaches to fight cancer."

Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: "It’s hugely exciting to be able to accelerate the development of a drug that could change outcomes for patients with many different types of cancer.

"In particular we urgently need new ways to improve treatment for lung cancer, which causes more than one in five of all cancer deaths in the UK.

"Without this collaboration it might have been years before this treatment reached patients so we‘re pleased to work with Biotecnol to elevate their novel drug development platform."